Douglas D. Cary, R.Ph., M.B.A.
President, CEO and Director
• Developed AddVantage® & Patient-Controlled Analgesia® at Abbott (cumulative sales over $1B).

Lewellys F. Barker, M.D., M.P.H.
Executive VP, Chief Scientific Officer and Director
• Led the development of diagnostic products for testing blood for hepatitis and HIV at the American Red Cross and FDA.

Stephen D. Cary, M.B.A.
Director
• Launched GlaxoSmithKline’s smoking cessation product, Zyban®.

Lester M. Crawford, D.V.M., Ph.D.
Director
• Former Commissioner of the FDA and Senior Counsel at Policy Directions Inc., a Washington, D.C. based government relations/strategic government communications firm.

Andrew R. Menard, J.D.
Vice President and Director
• Negotiated several pharmaceutical licensing agreements (e.g., Pepcid Complete® with J&J).

Stephen L. Norris, J.D., L.L.M.
Director
• Co-founder and Past President of the Carlyle Group, a private merchant bank located in Washington, D.C. and Chairman of SN Partners, a private equity investment firm.

Carl C. Schwan, M.B.A., C.P.A.
Executive VP, Chief Financial Officer and Director
• Completed IPOs at BioReliance and North American Vaccine.

Thomas J. Stuart, C.P.A.
Group President of Oral Technologies, Catalent Pharma Solutions
• Pursuant to our Agreement with Catalent, Catalent has appointed Mr. Stuart as its representative to attend meetings of the Company’s Board of Directors in a nonvoting, observer capacity.